F41

A patient F19... who is at clinical risk or a patient who is pregnant or aged 65 years or over, or who is aged under 65 years and is at risk of developing medical complications for influenza, where—

a

the Welsh Ministers have notified general medical practitioners that the influenza virus is circulating in the community;

b

the patient has an influenza-like illness; and

c

the patient can start therapy within 48 hours of the onset of symptoms.

2

A patient F19... who is at clinical risk or a patient who is pregnant or aged 65 years or over, or who is aged under 65 years and is at risk of developing medical complications for influenza, where—

a

it has been determined in accordance with a community based virological surveillance scheme that influenza A or influenza B is circulating in the locality in which the patient resides or is present or was present at the time that the virus was circulating;

b

the patient has an influenza-like illness; and

c

the patient can start therapy within 48 hours of the onset of symptoms.

3

Any patient suffering from influenza during an outbreak of pandemic influenza (influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza), where the drug is ordered under arrangements for the distribution of the drug free of charge which are approved by the Welsh Minsters.

4

A patient F19... who is at clinical risk or a patient who is pregnant or aged 65 years or over, where—

a

the Welsh Ministers have notified general medical practitioners that the influenza virus is circulating in the community;

b

the patient has been exposed to an influenza-like illness through being in close contact with someone with whom he lives who is or has been suffering from an influenza-like illness;

c

the patient is not effectively protected by vaccination against influenza because—

i

he has not been vaccinated because vaccination is contraindicated;

ii

he has not been vaccinated since the previous influenza season;

iii

he has been vaccinated but it has yet to take effect; or

iv

he has been vaccinated but the vaccine is not well matched to the strain of influenza circulating in the locality in which the patient resides or is or has been present;

d

the patient lives in a residential care establishment and another resident or member of staff of the establishment has an influenza-like illness; and

e

the patient can start prophylaxis within 48 hours of exposure to an influenza-like illness.

5

A patient F19... who is at clinical risk or a patient who is pregnant or aged 65 years or over, where—

a

it has been determined in accordance with a community based virological surveillance scheme that influenza A or influenza B is circulating in the locality in which the patient resides or is present or was present at the time that the virus was circulating;

b

the patient has been exposed to an influenza-like illness through being in close contact with someone with whom he lives who is or has been suffering from an influenza-like illness;

c

the patient is not effectively protected by vaccination against influenza because—

i

he has not been vaccinated because vaccination is contraindicated;

ii

he has not been vaccinated since the previous influenza season;

iii

he has been vaccinated but it has yet to take effect; or

iv

he has been vaccinated but the vaccine is not well matched to the strain of influenza circulating in the locality in which the patient resides or is or has been present;

d

the patient lives in a residential care establishment and another resident or member of staff of the establishment has an influenza-like illness; and

e

the patient can start prophylaxis within 48 hours of exposure to an influenza-like illness.

6

Any patient at risk from influenza during an outbreak of pandemic influenza (influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza), where the drug is ordered under arrangements for the distribution of the drug free of charge which are approved by the Welsh Ministers.

F141

The following patients with erectile dysfunction—

a

a man with erectile dysfunction who on 14th September 1998 was receiving a course of treatment under the Act, the National Health Service (Scotland) Act 19783 or the Health and Personal Social Services (Northern Ireland) Order 19724 for this condition with any of the following drugs—

• Alprostadil (Caverject), (MUSE), (Viridal)

• Apomorphine Hydrochloride (Uprima)

• Moxisylyte Hydrochloride Assembly (Erecnos)

• Sildenafil (Viagra)

• Tadalafil (Cialis)

• Thymoxamine Hydrochloride (Erecnos); or

F22b

a man who is a national of an EEA State who—

i

immediately before IP completion day was entitled to treatment by virtue of Article 7(2) of Council Regulation 1612/68 as extended by the EEA Agreement or was entitled to treatment by virtue of any other enforceable EU right,

ii

has erectile dysfunction and was on 14th September 1998 receiving a course of treatment under a national health insurance system of an EEA State for that condition with any of the drugs listed in sub-paragraph (a), and

iii

immediately before IP completion day was receiving a course of treatment as part of the health service for the condition mentioned in paragraph (ii) of this sub-paragraph with any of the drugs listed in sub-paragraph (a), or

F23c

a man who is not a national of an EEA State but who is the member of the family of such a national and who—

i

immediately before IP completion day had an enforceable EU right to be treated no less favourably than the national in the provision of medical treatment,

ii

has erectile dysfunction and was on 14th September 1998 receiving a course of treatment for that condition with any of the drugs listed in sub-paragraph (a), and

iii

immediately before IP completion day was receiving a course of treatment as part of the health service for the condition mentioned in paragraph (ii) of this sub-paragraph with any of the drugs listed in sub-paragraph (a), or

d

a man who is suffering from any of the following—

• diabetes

• multiple sclerosis

• parkinson’s disease

• poliomyelitis

• prostate cancer

• severe pelvic injury

• single gene

• neurological disease

• spina bifida

• spinal cord injury; or

e

a man who is receiving treatment for renal failure by dialysis; or

f

a man who has had the following surgery —

• prostatectomy

• radical pelvic surgery

• renal failure treated by transplant

F5g

a man who has been diagnosed as suffering severe distress resulting from erectile dysfunction where the assessment has been made by a specialist service or GP under arrangements made with a Local Health Board to provide such assessmentsF15;

2

Any patient

F61

A patient who is aged 5 years or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, or who is aged under 65 years and is at risk of developing medical complications from influenza, where—

a

the Welsh Ministers have notified general medical practitioners that the influenza virus is circulating in the community;

b

the patient has an influenza-like illness; and

c

in the case of a patient—

i

who has attained the age of 5 years but not the age of 13 years, that patient can start therapy within 36 hours of the onset of symptoms;

ii

who is aged 13 years or over, that patient can start therapy within 48 hours of the onset of symptoms.

2

A patient who is aged 5 years or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, or who is aged under 65 years and is at risk of developing medical complications from influenza where—

a

it has been determined in accordance with a community based virological surveillance scheme that influenza A or influenza B is circulating in the locality in which the patient resides or was present at the time that the virus was circulating;

b

the patient has an influenza-like illness; and

c

in the case of a patient—

i

who has attained the age of 5 years but not the age of 13 years, that patient can start therapy within 36 hours of the onset of symptoms;

ii

who is aged 13 years or over, that patient can start therapy within 48 hours of the onset of symptoms.